Name of journal: World Journal of Clinical Cases
Manuscript NO: 86513
Title: Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 00068967
Position: Editorial Board
Academic degree: MSc, PhD
Professional title: Academic Fellow, Deputy Director, Full Professor, Professor, Senior Editor
Reviewer’s Country/Territory: China
Author's Country/Territory: South Korea
Manuscript submission date: 2023-06-23
Reviewer chosen by: AI Technique
Reviewer accepted review: 2023-06-24 06:09
Reviewer performed review: 2023-06-24 06:56
Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No novelty</td>
<td></td>
</tr>
<tr>
<td>SPECIFIC COMMENTS TO AUTHORS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>As the authors stated, this study had the obvious limitation, only HR-positive/Her2-negative breast cancer patients with NAC were observed, other subtypes have not included would result in an inconcrete conclusion, or false positive outcome, to some extent. I recommend the authors to include the HER2-positive and triple negative breast cancer patients, to strengthen the comprehensive efficacy of this Gn-RH treatment, which would provide us a objective outcome. Furthermore, Suppression of Ovarian Function Trial presented a promising future for BC, while Gn-RH agonist using was contradicted to it, how do you consider it?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 86513

Title: Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 06290020

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: Brazil

Author’s Country/Territory: South Korea

Manuscript submission date: 2023-06-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-06-23 21:49

Reviewer performed review: 2023-06-29 00:41

Review time: 5 Days and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>Grade A: Excellent</td>
<td>Grade B: Good</td>
<td>Grade C: Fair</td>
<td>Grade D: No novelty</td>
<td></td>
</tr>
</tbody>
</table>

SPECIFIC COMMENTS TO AUTHORS

Choi et al purposed to investigate to look at the outcomes of HR-positive young breast cancer patients who received neoadjuvant chemotherapy (NAC) and the oncologic effectiveness of gonadotropin-releasing hormone (GnRH) agonists. In this way, they found that the Administration of GnRH agonists might improve the DFS rate of HR-positive/HER2-negative breast cancer in the equal to or younger than 35 years group of patients with NAC. In this way, they found that administering GnRH agonists may enhance the DFS rate of HR-positive/HER2-negative breast cancer among patients aged 35 or below. I found the study very interesting. I found the conclusion to be in line with the evidence and arguments presented. The article is well written. The figures and Tables are okay. I would, however, want to see Table 2, which the authors reference on page 4 (last line). In this manner, I would like to ask for a minor revision. Additionally, authors should provide the line numbers in the article.
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Clinical Cases
Manuscript NO: 86513
Title: Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind
Reviewer’s code: 00068967
Position: Editorial Board
Academic degree: MSc, PhD
Professional title: Academic Fellow, Deputy Director, Full Professor, Professor, Senior Editor

Reviewer’s Country/Territory: China
Author’s Country/Territory: South Korea
Manuscript submission date: 2023-06-23
Reviewer chosen by: Jia-Ping Yan
Reviewer accepted review: 2023-07-18 05:13
Reviewer performed review: 2023-07-18 05:22
Review time: 1 Hour

Scientific quality
[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good
[ ] Grade D: Fair [ ] Grade E: Do not publish

Language quality
[ ] Grade A: Priority publishing [ ] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
SPECIFIC COMMENTS TO AUTHORS
The authors have well addressed the issue.